New antifolates in clinical development.
Numerous new antifolate drugs have been developed in an attempt to overcome the potential mechanisms of tumor cell resistance to methotrexate, which can include decreased drug transport into cells; decreased polyglutamation, leading to increased drug efflux from cells; decreased drug affinity for folate-dependent enzymes; mutations of dihydrofolate reductase (DHFR), a key enzyme required for the maintenance of adequate intracellular reduced folate levels that is inhibited by methotrexate; and increased expression of the DHFR protein. Promising antifolate compounds undergoing clinical testing as anticancer agents include trimetrexate (which was recently approved by the FDA for the treatment of Pneumocystis carinii pneumonia), edatrexate, piritrexim, Tomudex, and lometrexol. The mechanisms of action, dosage, pharmacokinetics, clinical toxicity, and antitumor activity of these drugs are profiled.
Takimoto
C H
CH
Oncology Branch Bethesda Naval Hospital, Maryland, USA.
Allegra
C J
CJ
D000630:Aminopterin / Q000031:analogs & derivatives; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines; D011799:Quinazolines; D013876:Thiophenes; D016597:Trimetrexate
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D011799:Quinazolines; D013876:Thiophenes; C068874:raltitrexed; C040210:edatrexate; D000630:Aminopterin; C024530:piritrexim; D016597:Trimetrexate